Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
· fool.com · popularity 19/100 · 0 similar stories today · Corporate News & M&A (Business & Finance)
Read the original at fool.com →
Summary
Revenue for the vaccine maker rose sharply in the third quarter, but it was largely due to COVID sales, which have been down significantly over the …
Found in: The Motley Fool. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 7.